Showing results (231-240 of 259) with videos related to

Sort By:
Pageof 26
Blood|March 19, 2020
YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myelomaYan Xu, Mariateresa Fulciniti, Mehmet K Samur, et al.
Annals of Hematology|June 18, 2024
Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINEKeshu Zhou, Tingyu Wang, Ling Pan, et al.
Blood|September 24, 2024
Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINEJennifer R Brown, Barbara Eichhorst, Nicole Lamanna, et al.
Haematologica|January 18, 2024
Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumorsYuqin Song, Junning Cao, Qingyuan Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2022
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III TrialPeter Hillmen, Barbara Eichhorst, Jennifer R Brown, et al.
Leukemia|May 23, 2018
A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trialCharles Dumontet, Cyrille Hulin, Meletios A Dimopoulos, et al.
Blood Advances|November 1, 2021
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignanciesConstantine S Tam, Meletios Dimopoulos, Ramon Garcia-Sanz, et al.
Cell Metabolism|December 19, 2023
Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myelomaYinghong Zhu, Xingxing Jian, Shuping Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2023
The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical TrialTingyu Wang, Xiuhua Sun, Lihua Qiu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2025
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaJennifer A Woyach, Lugui Qiu, Sebastian Grosicki, et al.
Pageof 26